Clinical Trial Update: Improving the Efficacy of Experimental Malaria Vaccine AMA1-C1/Alhydrogel® (Registered Trademark) [Phase 1]

View source ↗

Summary

Phase 1 trial update on the malaria vaccine candidate AMA1-C1 formulated with Alhydrogel. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• AMA1-C1/Alhydrogel (AMA1-C1/Alhydrogel)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Healthy Volunteer, HV | Phase 1 | Status: COMPLETED